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Abstract
Background: Heightened local inflammation due to muscle trauma or disease is associated with impaired bone
regeneration.
Methods: We hypothesized that FK506, an FDA approved immunomodulatory compound with neurotrophic and
osteogenic effects, will rescue the early phase of fracture healing which is impaired by concomitant muscle trauma
in male (~4 months old) Lewis rats. FK506 (1 mg/kg; i.p.) or saline was administered systemically for 14 days after an
endogenously healing tibia osteotomy was created and fixed with an intermedullary pin, and the overlying tibialis
anterior (TA) muscle was either left uninjured or incurred volumetric muscle loss injury (6 mm full thickness biopsy
from middle third of the muscle).
Results: The salient observations of this study were that 1) concomitant TA muscle trauma impaired recovery of
tibia mechanical properties 28 days post-injury, 2) FK506 administration rescued the recovery of tibia mechanical
properties in the presence of concomitant TA muscle trauma but did not augment mechanical recovery of an
isolated osteotomy (no muscle trauma), 3) T lymphocytes and macrophage presence within the traumatized
musculature were heightened by trauma and attenuated by FK506 3 days post-injury, and 4) T lymphocyte but not
macrophage presence within the fracture callus were attenuated by FK506 at 14 days post-injury. FK506 did not
improve TA muscle isometric torque production
Conclusion: Collectively, these findings support the administration of FK506 to ameliorate healing of fractures with
severe muscle trauma comorbidity. The results suggest one potential mechanism of action is a reduction in local T
lymphocytes within the injured musculoskeletal tissue, though other mechanisms to include direct osteogenic
effects of FK506 require further investigation.
Keywords: Adaptive immune response, Composite injury, Inflammation, Immunomodulation, Musculoskeletal,
Open fracture, Orthopaedic trauma, Skeletal muscle injury, Volumetric muscle loss, Tacrolimus
Background
Approximately 5 – 50% of open fractures present either
delayed or non-union depending on injury severity and
location, and patient characteristics [1, 2]. The concomi-
tant loss of surrounding muscle tissue has been associ-
ated with poor healing outcomes in open fracture
patients [2, 3] and experimentally confirmed in animal
models [4, 5]. There are likely multiple mechanisms by
which severe trauma to the surrounding musculature
may impair fracture healing, to include impaired revas-
cularization, loss of muscle-derived stem cells that sup-
port bone regeneration, and alteration of the local milieu
of muscle-derived growth factors and myokines [6, 7].
However, heightened and prolonged immune responses
are inherent to trauma [8] and are a principle mediator
of musculoskeletal healing. It is therefore plausible that
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severe muscle trauma compounds the local immune
response and thereby impairs fracture healing.
We recently described the recruitment of CD4+ (helper)
and CD8+ (cytotoxic) T lymphocytes to both damaged
muscle and fracture callus following complex musculoskel-
etal injury [4]. The recruitment of T lymphocytes was
amplified through 28 days post-injury in comparison to a
simple fracture and was associated with impaired healing
[4]. CD4+and CD8+ T lymphocytes are key components of
the adaptive immune system and have been shown to regu-
late musculoskeletal tissue degeneration and repair [9, 10].
However, depletion studies also implicate lymphocytes as
deleterious to fracture repair [11]. For instance, CD4+ T
cells can negatively influence the receptor activator of NF-
kB-ligand/receptor activator of NF-kB/osteoprotegerin
(RANKL/RANK/OPG) osteoclastogenesis pathway by acti-
vating stromal cells via cytokines and CD40-CD40L inter-
actions and by activating bone destructing osteoclasts
through the production of cytokines (RANKL and IL-17)
[12]. CD8+ T cells may also negatively influence fracture
healing [13], however exact mechanisms are not well
defined. Altogether, the activation, polarization, differ-
entiation, and magnitude of specific T cell functions
are influenced by the complexity of injury and may
be both beneficial and detrimental for musculoskeletal
regeneration.
Therapeutically targeting T lymphocytes is an attractive
strategy to restore fracture healing following severe mus-
culoskeletal trauma. A viable tool is FK506 (Tacrolimus)
because it both directly and indirectly inhibits T cell
mediated immune responses [14]. Tacrolimus is an FDA
approved macrolide that inhibits IL-2 dependent T cell
activation by inhibiting enzymatic activity of calcineurin
and subsequent translocation of transcription factor nu-
clear factor of activated T cells (NFAT) [14]. FK506 is also
effective in reducing gene expression of pro-inflammatory,
but not anti-inflammatory cytokines [14] and therefore
potentially promotes T helper 2 (Th2) versus T helper 1
(Th1) responses. Moreover, FK506 has been shown to dir-
ectly mediate osteogenic differentiation of mesenchymal
stem cells in vitro [15], and therefore may augment chal-
lenged fracture healing in vivo [16]. FK506 also has neuro-
trophic properties that may improve functional recovery
of the traumatized musculature [17]. That being said, the
treatment of simple fractures or rhBMP-2 treated segmen-
tal defects with systemic administration of FK506 did not
augment fracture healing [16, 18]. However, it remains
plausible that fracture healing impaired by compounding
inflammation secondary to concomitant muscle trauma
(i.e., open fracture) [4] may be rescued by FK506.
In the current study, we primarily tested the hypoth-
esis that systemic FK506 administration improves the
recovery of mechanical strength of fractured tibia when
accompanied by comorbid muscle trauma using an
established rat model of open fracture [4]. As a putative
mechanism, the effect of FK506 administration on the
innate and adaptive immune responses in the injured
bone and muscle were evaluated.
Methods
Animals
All protocols and animal care guidelines were approved
(A14-033) by the Institutional Animal Care and Use
Committee at the United States Army Institute of Surgical
Research. All components were conducted in compliance
with the Animal Welfare Act, the Implementing Animal
Welfare Regulations and in accordance with the principles
of the Guide for the Care and Use of Laboratory Animals.
Inbred male Lewis rats (350-400 g; ~4 months of age)
were purchased from Harlan Laboratories and housed
in a specific pathogen-free animal facility. All rats re-
ceived a pre-surgical (~30 min prior) administration of
buprenorphine-SR (1.2 mg/kg; s.c.) for pain manage-
ment and a post-surgical x-ray was taken to ensure
proper fracture fixation. All animals were euthanized
while heavily sedated, by injection of Fatal Plus (sodium
pentobarbital, 150 mg/kg; intracardiac).
Experimental design
Volumetric muscle loss (VML) injury has previously
been shown to impair endogenous healing of rat tibia
non-segmental osteotomy (OST) [4] and BMP-2 medi-
ated healing of a segmental defect (SD) in the rat tibia
[19] and femur [5]. The current work was designed to
determine if the immunomodulatory compound, FK506,
restores the early phase of recovery of tibia mechanical
properties during endogenous bone regeneration of
impaired fracture healing.
Male Lewis rats underwent surgical creation of an
endogenously healing tibia osteotomy (OST) with or
without concomitant ipsilateral tibialis anterior (TA)
muscle VML injury (OST + VML). Briefly, the OST was
performed approximately 5 mm proximal to the tibia-
fibula junction and stabilized with a 1.25 mm Kirschner
pin inserted in the medullary cavity from the tibial plat-
eau [4]. VML injury was surgically created in the middle
third of the adjacent TA muscle using a punch biopsy
(6 mm), as we have reported previously [20, 21]. X-rays
were acquired with 3 days post-injury to ensure ad-
equate tibia stabilization. Injured rats were allotted
randomly to systemic saline or FK506 treatment groups.
FK506 (1 mg/kg; Sigma-Aldrich) was administered in
sterile saline by daily injection (i.p.) beginning immedi-
ately after surgery and for 14 days post-injury, during
the primary period post-injury when the musculoskeletal
immune response is exacerbated in this model [4]. This
dosage of FK506 has previously been shown to induce a
therapeutic concentration of FK506 systemically [18].
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Rats were followed out to 28 days post-injury, at which
time musculoskeletal physiological and mechanical as-
sessments were performed (n = 6-8/group; Statistical
power (1-ß) was approximately 0.7). Previous reports
using this and similar models have indicated that at this
time post-injury fracture healing is not fully resolved,
permitting observations of an impaired rate of healing
by concomitant VML injury [4, 22, 23]. To determine if
FK506 attenuated the cellular immune response in
OST + VML, muscles samples were harvested at 3 days
post-injury for flow cytometric analysis (n = 4/group).
Additionally, tibiae were collected at 3 and 14 days post-
injury, in a follow-on analysis for quantitative immuno-
histological analyses (n = 3/group; Fig. 1).
Bone mechanical testing
Three-point bending was performed on a set of rat tibiae
at 28 days post-injury, using methods previously de-
scribed [4]. Load-deflection curves were used to obtain
maximum load and stiffness.
Muscle functional assessment
In vivo functional testing of TA muscles was performed
at 28 days post-injury using methodology previously
described [20, 21, 24]. Briefly, TA muscle in vivo physio-
logical properties were measured in anesthetized rats
(isoflurane 1.5 – 2.0%) using a dual-mode muscle lever
system (Aurora Scientific, Inc., Mod. 305b). Subcutane-
ous needle electrodes were inserted in the posterior
compartment of the lower limb on each side of the com-
mon peroneal nerve. Optimal voltage (2 – 5 V) was set
with a series of tetanic contractions (5 – 10 contractions;
150 Hz, 0.1 ms pulse width, 400 ms train). Then, a skin
incision was made at the antero-lateral aspect of the
ankle and the distal tendons of the extensor digitorum
longus and extensor hallicus longus muscles was isolated
and severed above the retinaculum [20]. TA muscle
maximal isometric tetanic torque was measured
(150 Hz) with the ankle at a right angle.
Cellular isolation from muscle tissue
Cells were isolated from the middle third of the TA
muscle that encompassed the muscle defect by enzymatic
digestion as previously described [4]. Briefly, the defect
was surgically isolated and the mass was determined.
Tissue was incubated with collagenase type II and dispase
for 90 min at 37 °C. Cells were further released by gentle
mechanical disruption and filtered through a 70 μm cell
strainer. Erythrocytes were lysed with ammonium-
chloride-potassium lysing buffer and cells were filtered
through a 40 μm cell strainer washed, and resuspended in
PBS containing 0.5% FBS and 0.1% sodium azide. Viable
cells were quantified using trypan blue exclusion and a
hemocytometer.
Quantification of cellular infiltrates in muscle defect by
flow cytometry
Muscle-derived cells were labeled with fluorochrome-
conjugated antibodies and analyzed by flow cytometry as
previously described [4]. Cells were incubated with anti-
CD32 antibody to block Fc receptors and labeled with
either cocktail monoclonal antibodies to identify macro-
phages or T lymphocytes. The macrophage (MØ) cell
cocktail included anti-CD45 (clone OX-1), anti-CD11b
(WT.5), anti-CD68 (ED1), anti-CD86 (24F), and anti-
CD163 (ED2). The T lymphocyte cell cocktail consisted of
anti-CD45, anti-CD3 (IF4), anti-CD4 (OX-35), and anti-
CD8α (OX-8). Labeled cells were fixed with 1% parafor-
maldehyde and enumerated by fluorescence-activated cells
sorting using a MACSQuant flow cytometer (Miltenyi
Biotec). Data were analyzed using MACSQuantify software
(Miltenyi Biotec). Gating strategies to identify cellular pop-
ulations included the following: CD45+ hematopoietic cells,
CD45+CD11b+CD68+ MØ, CD45+CD11b+CD68+CD86+
M1-like MØ, CD45+CD11b+CD68+CD163+ M2-like MØ,
CD45+CD3+CD4+ T helper and CD45+CD3+CD8α+ T
cytotoxic lymphocytes. Cell numbers of each gated popula-
tion were determined by multiplying the percentage of cells
by the total number of viable cells recovered from the re-
spective defect. All cell numbers were normalized per gram
of excised muscle tissue.
Histology
Tibiae were fixed in 10% neutral buffered formalin and
decalcified in a formic acid bone decalcifier (Immuno-
cal, Decal Chemical Corp, Tallman NY) using similar
methodology as previously described [4]. Samples were
0 3 14 28 
Trauma 
Flow cytometry 
Immunohistology Strength
testing 
FK506 or Saline (i.p.; daily) 
Days post injury  
Fig. 1 Experimental time course. The schematic depicts the
therapeutic regimen (FK506 or saline) and experimental assays
carried out over the course of 28 days post OST + VML. Trauma
consisting of OST + VML was generated at day 0. FK506 or saline
control was administered daily by the intraperitoneal route from
day 0 to day 14 following injury. At 3 days post-injury, flow cytometry
and immunohistochemical analysis of damaged muscle and adjacent
fracture region was carried out, immunohistochemical analysis was
also analyzed at 14 days post-injury. At 28 days post-trauma strength
testing assays of bone and muscle were carried out
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processed in paraffin and embedded in a longitudinal
orientation. Tibiae were cut in 8 μm sections and
deparafinized. Immunohistochemical (CD4, BioRad:
MCA55GA, 1:100; CD8a, BD Pharmingen: 550,298,
1:100; CD68, BioRad: MCA341R, 1:200) staining was
performed using standard methodology.
Bright field images were acquired with a Zeiss Axio
Scan.Z1 and stitched into a large composite image.
Composite images were saved separately as a 24-bit, 96
dpi color images. All images were analyzed in MetaMorph
(Molecular Devices LLC., Sunnyvale CA). For display pur-
poses only, images were produced in Keynote by down-
converting, without introducing any changes in brightness
or contrast. With each inflammatory marker (CD4, CD8,
and CD68) the region of the callus between the bone and
on the anterior aspect of the tibia was selected for analysis,
care was taken to not select mineralized bone or skeletal
muscle fibers (Additional file 1). The image was color
thresholded (hue, saturation, and intensity) to identify in-
dividual inflammatory markers (by saturation threshold).
The percentage of area covered was determined off of the
area of the total selected region and were analyzed using
binary images. Analyses were conducted by an investigator
blinded to treatment group; in the event that multiple
serial sections from a single tibia stained for the same in-
flammatory marker the percent area from each section
was averaged and used for analysis (n = 3 rats/group/
time/marker). Tibiae sections used as negative controls
were used to verify analysis of inflammatory markers.
Statistics
Dependent variables were analyzed using one- or two-
way ANOVA or Student’s t-test. In the event of a signifi-
cant ANOVA, Fisher’s post-hoc testing was performed.
Statistical significance was achieved at alpha of 0.05.
Statistical testing was performed using Prism 6 for Mac
OSX (Graphpad Inc). Data is presented as box (25 to 75
percentile with median line) and whisker (minimum and
maximum response) plots.
Results
Systemic FK506 administration improves healing of
fracture with concomitant VML injury but not recovery of
muscle strength
Previously, the immunomodulatory drug FK506 did not
improve healing of a simple femur OST without con-
comitant muscle trauma [18]. Herein, FK506 delivery
also failed to improve healing of an isolated tibia OST,
evidenced by similar mechanical properties of injured
OST-only tibiae from saline or FK506-treated rats
28 days post-injury (Fig. 2a & b). However, often fracture
occurs with a concomitant loss of surrounding muscula-
ture (e.g., Gustilo-Anderson type II and III open frac-
ture), which can impair bone regeneration [4]. In a
model of this clinical scenario, VML injury significantly
reduced (OST + VML-saline) tibia mechanical strength
(−41%; p = 0.028) and stiffness (−54%; p = 0.039) com-
pared to OST-only groups 28 days post-injury, with 5 of
6 observations in the OST + VML-saline group having
0
20
40
60
80
150
200
250
M
ax
im
um
 L
oa
d 
 (M
P
a)
OST OST+VML
0
2
4
6
8
10
12
S
tif
fn
es
 (G
P
a)
OST OST+VML
0
20
40
60
80
150
200
250
M
ax
im
um
 L
oa
d 
 (M
P
a)
OST OST+VML
0
2
4
6
8
S
tif
fn
es
 (G
P
a)
OST OST+VML
Saline+ + FK506
CONTRALATERAL INJUREDa 
c 
b 
d 
* 
* 
* 
Fig. 2 Mechanical testing of bone following FK506 treatment of OST + VML injury. Three-point bending mechanical testing of (a & c) contralateral
and (b & d) injured tibiae was performed at 28 days post-injury. * ≠ OST-saline & OST + VML-FK506; p < 0.05. Group responses are presented as
box (25 to 75 percentile with median line) and whisker (minimum and maximum response) plots; n = 6-8/group
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mechanical property values lesser than the median re-
sponse of OST-saline (Fig. 2). Coinciding with dimin-
ished mechanical strength in the injured limb, the
contralateral tibia mechanical strength was significantly
increased in OST + VML treated with saline, compared
to all other groups (p < 0.001). Notably, FK506 restored
tibia mechanical properties in OST + VML rats to OST-
only levels (Fig. 2b).
The effect of FK506 administration on in vivo isometric
TA muscle strength was also assessed 28 days post-injury
(Fig. 3). In OST-only groups, TA muscle strength was
similar between saline and FK506-treated rats (p = 0.112).
The surgical creation of VML injury (OST + VML-saline)
resulted in a 33% decrease in neural-evoked isometric
torque compared to OST-saline (p < 0.001), and FK506
administration did not ameliorate TA muscle strength
deficits (OST + VML-saline vs. –FK506: p = 0.492).
Systemic FK506 administration modulates the immune
response within VML injured muscle
VML injury induces a heightened and prolonged local
pro-inflammatory immune response within the trau-
matized musculature that associates with impaired
fracture healing [4]. To investigate the effect of sys-
temic FK506 administration on the immune response
to VML injury, first flow cytometric quantification of
TA muscle infiltrating CD45+CD3+CD4+ (T helper)
and CD45+CD3+CD8+ (T cytotoxic) lymphocytes was
performed 3 days post-injury (Fig. 4a). In OST + VML
groups, FK506 significantly reduced the number of
CD45+CD3+CD4+ cells by 51% (p = 0.037). CD45+CD3
+CD8+ cells were not significantly reduced by FK506
treatment (−43%; p = 0.087; Fig. 4b - d).
The effect of FK506 therapy on macrophage popula-
tions recruited to damaged muscle at 3 days post-injury
was also investigated. Again, using flow cytometry we
quantified muscle infiltrating CD45+ (hematopoietic),
CD45+CD11b+CD68+ (MØ), CD45+CD11b+CD68+CD86+
(M1-like MØ), and CD45+CD11b+CD68+CD163+ (M2-like
MØ) cells (Fig. 5a). FK506 reduced CD45+ hematopoietic
cells by 24% (p = 0.008) and CD68+ macrophages by 22%
(p = 0.013), but had no significant effect on M1 and M2
polarization or recruitment in comparison to saline treated
animals (Fig. 5b - e).
Fracture site infiltration of T lymphocytes but not
macrophages is attenuated by systemic FK506
As a potential link between heightened muscle inflam-
mation and impaired fracture healing, it has been ob-
served that conditions of heightened local and systemic
inflammation correspondingly protract fracture site in-
flammation and disrupt bone regeneration [4, 25]. To
further establish this relationship, the presence of CD4+
and CD8+ T cells and CD68+ macrophages was quanti-
fied within the fracture callus at 3 and 14 days post-
injury in saline or FK506-treated rats with OST + VML
injury (Fig. 6). No differences in macrophage or lympho-
cyte markers were observed between groups during the
early phase of repair at 3 days post-injury. At 14 days
post-injury, the fractional area of CD68+ expression was
elevated in saline and FK506-treated rats compared to
3 days post-injury, but again no difference in macro-
phage marker presence was observed. The fractional
area of both CD4+ and CD8+ expression was signifi-
cantly elevated compared to 3 days post-injury in
OST + VML treated with saline, which was significantly
attenuated in FK506 treated rats (OST + VML-saline
vs. -FK506: CD4+ p = 0.008; CD8+ p = 0.001).
Discussion
The primary finding of this study is that the FDA ap-
proved immunomodulatory drug, FK506 (Tacrolimus),
improves the early recovery of tibia mechanical properties
following osteotomy with concomitant severe muscle
trauma (i.e., VML injury). Notably in this endogenously
healing fracture model [4] and others that require rhBMP-
2 treatment to recover [5, 19], VML injury impairs frac-
ture healing and therefore the improvement in mechanical
strength mediated by FK506 delivery reflects a restoration
of the rate of endogenous fracture healing. These findings
support the exploration of immunomodulatory therapies
for augmentation of impaired fracture healing secondary
to a loss of surrounding muscle tissue (e.g., type II and IIIa
tibia open fracture).
In polytrauma and myopathy, heightened inflammation
has been coupled with either poor fracture healing or poor
bone health [25–29]. In each of these conditions,
Fig. 3 TA muscle strength assessment after FK506 therapy. In
vivo peak isometric tetanic torque was assessed at 28 days
post-injury. *each OST + VML group < respective OST group,
p < 0.05. Group responses are presented as box (25 to 75
percentile with median line) and whisker (minimum and
maximum response) plots; n = 6-8/group
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immunomodulation (i.e., macrophage or complement
inhibition) has effectively improved bone healing [25, 30].
Similarly, under conditions of exacerbated inflamma-
tion, such as implantation of xenogeneic deminera-
lized bone grafts in the abdominal musculature [31] or
genetically modified xenogeneic muscle implants into
femur segmental defect [16], FK506 has improved
bone formation. However, previous work has shown
that FK506 does not improve endogenous or rhBMP-2
mediated fracture healing without extensive muscle
trauma [16, 18], which is likely because fractures with-
out large muscle trauma do not result in excessive
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local immune responses [4]. The current findings agree
with Voggenreiter et al. [18], as FK506 did not enhance
healing of an osteotomy without VML injury, but go on to
demonstrate that FK506 re-establishes the early recovery
of mechanical properties in the presence of concomitant
VML injury, which elicits exacerbated inflammation. In
association with improved tibia mechanical properties,
FK506 administration reduced the acute infiltration of T
cells and macrophages in VML-injured musculature and
T cells in the fractured bone within the first 2 weeks post-
injury. These data therefore support further testing of the
broad working hypotheses that: 1) VML injury prompts a
heightened local immune response that disrupts fracture
healing and 2) that an immunomodulatory therapy (e.g.,
FK506) normalizes the musculoskeletal immune response,
and thereby rescues fracture healing.
While FK506 ameliorated the recovery of tibia mech-
anical properties, treatment did not improve neuro-
muscular strength after VML injury. Muscle strength
deficits after VML injuries have been primarily attrib-
uted to the traumatic loss of contractile tissue [32, 33].
However, strength deficits are at least partially com-
pounded by acute intramuscular nerve damage and it is
suspected that the heightened immune response to
VML injury causes secondary muscle damage. Given
the well-known neurotrophic effects of FK506 [17, 34],
it was therefore anticipated that FK506 administration
would improve functional recovery of the remaining
muscle mass. The systemic dose (1 mg/kg) used in this
study was adequate to attenuate macrophage and
lymphocyte infiltration within VML injured muscle,
however, this dose has conflicting results regarding per-
ipheral nerve regeneration [35, 36]. Collectively, these
findings indicate that while attenuation of the height-
ened local immune response caused by VML injury
may be beneficial to fracture healing, continued efforts
are required to improve skeletal muscle regeneration
and recovery of strength.
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Fig. 6 Evaluation of immune cells infiltrating fracture callus of OST + VML treated with FK506 using immunohistological staining. Injured tibiae
were collected at 3 and 14 days post-injury from OST + VML injured groups that received saline or FK506 treatment. Tissue was sectioned and
immunohistochemical analysis was carried out to detect CD68+ macrophages, CD4+ T cells, and CD8+ cytotoxic T cells, using horseradish
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Improvement of fracture healing by FK506 was consist-
ently associated with attenuated T lymphocyte infiltration
within the traumatized muscle and bone. Given that T
lymphocytes have been shown to drive the development
and function of osteoclasts through the production of the
pro-inflammatory cytokine IL-17 and RANKL [37], FK506
mediated attenuation of this degenerative interaction may
explain the improved fracture healing. The restorative ef-
fects of FK506 on fracture healing may also occur through
modulation of multiple types of immune cells. Several re-
ports suggest FK506 modulates innate immune cells to
generate reduced responses to innate stimuli [38–40]. For
example, dendritic cells and macrophages pretreated with
FK506 were shown to produce lower amounts of pro-in-
flammatory cytokines after exposure to lipopolysacchar-
ide, a pathogen associated molecular pattern (PAMP)
[38, 39]. PAMPs and damage-associated molecular pat-
terns (DAMPs) both signal through Toll-like receptor
(TLR) pathways that are damped in TLR-ligand stimu-
lated peripheral blood mononuclear cells isolated from
patients who received FK506 [40]. FK506 also affects
the regulatory T (Treg) cell population, which is known
to dampen pro-inflammatory immune responses [41]. It
is clear that the entire T cell population is not detri-
mental to fracture repair but instead individual T cell
subsets uniquely regulate or impair the fracture repair
process [13, 42–46]. Given the myriad of cellular tar-
gets upon which FK506 may interact and general IL-2-
mediated suppression of T lymphocytes by FK506, fur-
ther study is required to assess whether such a broad
therapeutic effect is necessary to restore fracture heal-
ing after severe musculoskeletal trauma.
We were surprised by the differential response of mac-
rophages in the bone and muscle tissue. A previous report
of mdx mouse pathology demonstrated a coordinated
macrophage response between diseased muscle and adja-
cent fracture bone that corresponded with impaired
fracture healing [25]. However, FK506 reduced CD45+
cells, which were primarily (>90%) comprised of CD68+
macrophages, in the muscle 3 days post-injury while cell
numbers of this population were unchanged in the frac-
ture site at 3 or 14 days post-injury. It is possible that the
reduction of macrophages in the muscle could lead to
overall reduced pro-inflammatory cytokine/chemokine
levels that impact downstream wound healing events in
muscle and bone. Alternatively, the activation levels of
macrophages at the fracture may be reduced to allow for
improved wound healing despite the cell numbers being
unaltered by FK506. Further investigation is required to
conclusively determine the impact of the macrophage
response on fracture healing following complex mus-
culoskeletal trauma.
It has been established that local musculature provides
vascular, paracrine, mechanical, and cellular support to
adjacent bone [6, 7]. The partial loss of surrounding
skeletal muscle in similar rodent open fracture models
indicate that associated impairment of fracture healing is
not necessarily driven by deficient revascularization of
the fracture [22, 23], highlighting a potential deficiency
in the activity of myokines [47–49] and muscle derived
stem cells [50, 51] in the support of fracture healing
under these conditions. Interesting interplay between
immune responses and IGF-1 signaling [52] and muscle
stem cells [53] support the idea that that while con-
trolled inflammation is beneficial to muscle-bone com-
munication, exacerbated inflammation following severe
soft tissue trauma may restrict muscle derived support
of osseous regeneration and thus contribute to impaired
fracture healing.
FK506 may also directly influence osteoblast and
osteoclast activity [54–58] and thereby improve fracture
healing. Notably, FK506 has also been shown to promote
osteogenic differentiation of mesenchymal stem cells via
BMP receptor signaling in vitro [15], highlighting the
potential utility of this compound as an osteoinductive
agent. In vivo FK506 had no effect on the quantity but
improved the quality of bone formation in xenogeneic
muscle graft-treated femur defect in athymic rats, poten-
tially reflecting direct osteoblast/clast augmentation [25].
In relation to fracture healing, it is interesting that in
animal models with a competent immune system, FK506
does not appear to augment endogenous or rhBMP-2 me-
diated bone regeneration when comorbid muscle trauma
is not explicitly introduced, see Fig. 2 and [16, 18]. These
findings suggest that in vivo the direct osteogenic effects
of FK506 are more influential under conditions of height-
ened inflammation. Suffice to say that while impaired
bone regeneration following open fracture can be driven
by the dysregulated immune response provoked by VML
injury [4], rescued fracture healing by FK506 may not be
strictly related to immunomodulation.
There remain numerous questions regarding the use
of FK506 or other immunomodulatory compounds for
open fracture that are not addressed in this work.
Notably, it is unclear whether FK506 is effective if de-
livered in a delayed manner, which is the likely clin-
ical scenario. Relatedly, it is unclear if FK506 can be
delivered either locally or systemically at an effective
dose for musculoskeletal healing without potentiating
infection. While these salient limitations are import-
ant to clinical translation, this initial study highlights
the utility of FK506 in improving regeneration following
complex musculoskeletal trauma.
Conclusions
In summary, the present study offers initial evidence that
reduction of the dysregulated immune response trig-
gered by complex musculoskeletal injury with FK506, an
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FDA-approved drug (Tacrolimus), may play a role in
rescuing impaired fractured healing; however, direct
osteoinductive activity of the compound may also influ-
ence early fracture healing. In agreement with previous
lymphocyte depletion studies [11], herein the data asso-
ciate heightened T cell but not macrophage recruitment
to the fracture site with impaired recovery of mechanical
properties early during the fracture healing process. The
current study also suggests that a mere attenuation of T
cell infiltration within injured bone and adjacent muscle
associates with improved bone healing. The results of
this study highlights the potential of immunomodulatory
drugs to treat orthopaedic musculoskeletal trauma and
supports previous findings that the net T cell response
to complex musculoskeletal injury is dysfunctional for
efficient fracture healing.
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